Otsuka Pharmaceutical: Difference between revisions

From Azupedia
Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 11: Line 11:
| romanized_name  = Ōtsuka Seiyaku Kabushiki-gaisha
| romanized_name  = Ōtsuka Seiyaku Kabushiki-gaisha
| former_name        =  
| former_name        =  
| type              = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| type              = [[:en:Public company|Public]] [[:en:Kabushiki gaisha|KK]]
| traded_as          = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| traded_as          = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| ISIN              =  
| ISIN              =  
| industry          = [[Pharmaceutical industry|Pharmaceutical]]
| industry          = [[Pharmaceutical industry/ja|Pharmaceutical]]
| genre              =  
| genre              =  
| fate              =  
| fate              =  
Line 22: Line 22:
| founder            = Busaburo Otsuka
| founder            = Busaburo Otsuka
| defunct            =  
| defunct            =  
| location_city      = [[Chiyoda, Tokyo|Chiyoda]], [[Tokyo]]
| location_city      = [[:ja:東京都|東京都]][[:ja:千代田区|千代田区]]
| location_country  = [[Japan]]
| location_country  = [[:ja:日本|日本]]
| location          =  
| location          =  
| coordinate        =  
| coordinate        =  
| locations          = 69
| locations          = 69
| area_served        = Worldwide
| area_served        = Worldwide
| key_people        = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small>
| key_people        = Tatsuo Higuchi <small>([[:en:President (corporate title)|President]])</small>
| products          =  
| products          =  
| brands            =  
| brands            =  
Line 45: Line 45:
| equity            =
| equity            =
| equity_year        =  
| equity_year        =  
| owner              = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| owner              = [[Wikipedia:Nomura Trust and Banking|Nomura Trust and Banking]] [[Wikipedia:investment trusts|investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| num_employees      = 5,634
| num_employees      = 5,634
| num_employees_year = 2017
| num_employees_year = 2017
Line 54: Line 54:
| footnotes          =
| footnotes          =
}}
}}
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[:en:Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.


==History==
==History==
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name=fujitoslodkowski2010>{{Citation |last1=Fujita |first1=Junko |first2=Antoni |last2=Slodkowski |editor=Nathan Layne |date=December 16, 2010 |publisher=Forexyard |access-date=January 15, 2012 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |type=[[Reuters]] news |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archive-date=March 4, 2012 }}</ref>
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]]. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.


===Otsuka Pharmaceutical Co. Ltd Holdings===
===Otsuka Pharmaceutical Co. Ltd Holdings===
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.<ref>{{cite web |title=Tokushima Vortis |date=15 January 2020 |url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ |access-date=October 30, 2020}}</ref>
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.


In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]].<ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 &#124; Otsuka People Talk }}</ref>
In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]].


In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]].<ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>
In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]].


In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web |title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. |url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html |website=otsuka.co.jp |access-date=October 30, 2020 |date=May 28, 2008}}</ref>
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].


In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref>{{Citation |date=January 13, 2012 |publisher=BioSpace |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |publisher=Zenopa|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.


In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref>
In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref>


In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.<ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=[[The New York Times]]|date=2 December 2014 |access-date=23 April 2018}}</ref>
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.


In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.


In July 2017, the business acquired [[Daiya]].<ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
In July 2017, the business acquired [[Daiya]].


In July 2018, Otsuka agreed to acquire Visterra for $430 million cash<ref>{{Cite web|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms|date=July 11, 2018}}</ref> and renal-focused ReCor Medical, Inc.<ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>
In July 2018, Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor Medical, Inc.


In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.
In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.
Line 106: Line 106:
* [[Pocari Sweat]]
* [[Pocari Sweat]]
* [[Oronamin C]]
* [[Oronamin C]]
* [[Aripiprazole|Aripiprazole / Abilify]]<ref>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>
* [[Aripiprazole|Aripiprazole / Abilify]]


==References==
{{Reflist}}


==External links==
==External links==

Revision as of 14:18, 19 November 2023

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Ōtsuka Seiyaku Kabushiki-gaisha
SectorPublic KK
TYO: 4578
TOPIX 100 Component
IndustryPharmaceutical
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
¥ 57.0 billion (2017)
OwnerNomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
ParentOtsuka Holdings Co. Ltd
Websiteotsuka.com

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.

Otsuka Pharmaceutical Co. Ltd Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.

In 1986, Otsuka Holdings Co. Ltd. acquired Ridge Vineyards.

In 1990, Otsuka Holdings Co. Ltd. acquired Crystal Geyser Water Company.

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.

In September 2013, Otsuka Holdings it acquired Astex Pharmaceuticals for close to $900 million.[1]

In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.

In July 2017, the business acquired Daiya.

In July 2018, Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor Medical, Inc.

In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.

Acquisition history

Otsuka Pharmaceutical Acquisitions

Products

Products of Otsuka Pharmaceutical


External links

  1. ↑ Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Otsuka_Pharmaceutical&oldid=76679"